University of Wyoming College of Health Sciences, School of Pharmacy, Laramie, WY 82071, United States.
Curr Drug Targets. 2018;19(9):1018-1023. doi: 10.2174/1389450117666160622220915.
Pancreatic cancer is predicted to be the second deadliest malignancy (a median survival of 4-6 months and a 5-year survival of less than 5%) in the USA by 2020. Although current medical detection technologies have dramatically improved the survival rate for patients with other gastrointestinal malignancies, the dismal clinical outcome remains somewhat unchanged for patients with pancreatic cancer. Preclinical evidence suggests that pancreatic cancer may be benefited from early administration of systemic therapy in addition to surgery. New biomarkers should help to identify those patients possibly candidates for various systemic therapy including chemotherapy. Classical anticancer drugs such as FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nabpaclitaxel plus gemcitabine only produced some modest improvements in survival. To this end, novel therapeutic avenues are sought for pancreatic cancer. This mini-review summarizes the state-of-the-art of pancreatic cancer treatment, and possible role of autophagy in therapeutics against pancreatic cancer.
预计到 2020 年，胰腺癌将成为美国第二大致死性恶性肿瘤（中位生存期为 4-6 个月，5 年生存率低于 5%）。尽管目前的医学检测技术极大地提高了其他胃肠道恶性肿瘤患者的生存率，但胰腺癌患者的临床预后仍然没有明显改善。临床前证据表明，除了手术之外，胰腺癌患者可能从早期全身治疗中获益。新的生物标志物有助于识别那些可能接受各种全身治疗（包括化疗）的患者。经典的抗癌药物，如 FOLFIRINOX（亚叶酸、5-氟尿嘧啶、伊立替康和奥沙利铂）和白蛋白紫杉醇联合吉西他滨，仅在生存方面略有改善。为此，人们正在寻找治疗胰腺癌的新途径。本综述总结了胰腺癌治疗的最新进展，以及自噬在治疗胰腺癌中的可能作用。
